Fundraising Fox

Versant Ventures β€” Full Portfolio

54 tracked investments Β· listed companies and verified rows first

Monte Rosa Therapeuticsmonterosatx.comin𝕏NASDAQ: GLUEβœ“ verified

Monte Rosa Therapeutics is a biopharmaceutical company developing molecular glue degrader (MGD) therapeutics using its QuEEN discovery engine, targeting oncology, neuroscience, and immune-mediated diseases.

AI & Machine LearningBiotechHealthtechBoston, US

Alexander Mayweg(Director)Bradley Bolzon(Director)Markus Warmuth(M.D., Chief Executive Officer)Kim Blackwell(Director)Sharon Townson(Ph.D., Chief Scientific Officer)John Castle(Ph.D., Chief Data and Information Officer)

Century Therapeutics, Inc.NASDAQ: IPSCMar 2021SEC filingmedium confidence

Philadelphia, US

Board seatCarlo RizzutoΒ· per SEC Form D Β· $160M raise Β· filed Mar 2021

Black Diamond TherapeuticsNASDAQ: BDTX
Capsidacapsida.cominπ•βœ“ verified

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.

BiotechDeep TechDigital HealthMedical Devices

Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)

Gate Biogatebio.comβœ“ verified

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical Devices

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in

Granite Biogranitebio.cominβœ“ verified

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)

858 Therapeutics, Inc.Jul 2024SEC filingmedium confidence

San Diego, US

Board seatClare OzawaMonal MehtaCarlo RizzutoΒ· per SEC Form D Β· $50.4M raise Β· filed Jul 2024

Aset TherapeuticsMar 2017SEC filingmedium confidence

BiotechStony Brook, US

Elizabeth Buck(Executive Officer)Garry E Menzel(Director)David M Epstein(Executive Officer, Director)Alexander Mayweg(Director)

Board seatBrad BolzonAlex MaywegΒ· per SEC Form D Β· $12.1M raise Β· filed Jan 2018

Bright Peak TherapeuticsJun 2024SEC filingmedium confidence

San Diego, US

Fredrik Wiklund(Executive Officer, Director)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)Alexander Mayweg(Director)Josh Resnick(Director)

Board seatTom WoiwodeAlex MaywegΒ· per SEC Form D Β· $90M raise Β· filed Jun 2024

Chinook Therapeutics U.SFeb 2019SEC filingmedium confidence

Seattle, US

Sam Hall(Director)Eric Dobmeier(Executive Officer, Director)

BoardSrini Akkaraju(Director)Jeremy Caldwell(Director)

Board seatJerel DavisΒ· per SEC Form D Β· $65M raise Β· filed Aug 2019

Concerto HealthcareJul 2015SEC filingmedium confidence

HealthtechIrvine, US

Timothy Petersen(Director)Edward Wristen(Director)Toby Thomas(Executive Officer)John Huntz(Director)Alec Cunningham(Executive Officer, Director)Cindy Becker(Executive Officer)

Board seatBarbara LubashΒ· per SEC Form D Β· $15.6M raise Β· filed Jul 2015

Enable Injectionsenableinjections.comin𝕏Dec 2025SEC filingmedium confidence

Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases.

BiotechHealthtechMedical DevicesCincinnati, US

Mike Hooven(Chairman, President and CEO)John Rice(Director)Timothy Flaherty(Executive Officer)Simone Song(Director)Karen Robards(Director)Richard J D'Augustine(Director)

Board seatBeckie RobertsonΒ· per SEC Form D Β· $30M raise Β· filed Jan 2026

Firefly Bio, Inc.Dec 2023SEC filingmedium confidence

South San Francisco, US

Board seatJerel DavisAlex MaywegΒ· per SEC Form D Β· $72M raise Β· filed Mar 2024

Graphite Bio, Inc.Mar 2021SEC filingmedium confidence

South San Francisco, US

Board seatJerel DavisCarlo RizzutoΒ· per SEC Form D Β· $150.7M raise Β· filed Mar 2021

Jengu Therapeutics, Inc.Sep 2020SEC filingmedium confidence

BiotechSan Diego, US

THOMAS WOIWODE(Director)ERIC FISCHER(Director)

BoardJEREMY CALDWELL(Executive Officer, Director)

Board seatClare OzawaΒ· per SEC Form D Β· $50M raise Β· filed Sep 2020

Jnana Therapeutics Inc.Jan 2024SEC filingmedium confidence

Boston, US

Board seatCarlo RizzutoΒ· per SEC Form D Β· $107M raise Β· filed Jan 2024

Lycia Therapeuticslyciatx.comJun 2026SEC filingmedium confidence

Lycia Therapeutics develops LYTAC degrader therapeutics designed to selectively reduce levels of disease-causing extracellular and membrane-bound proteins.

BiotechHealthtechSouth San Francisco, US

Tim Anderson(Director)William Rieflin(Director)Aetna Wun Trombley(Executive Officer, Director)Laurent Fischer(Director)Ming Fang(Director)Amy Bachrodt(Executive Officer)

Board seatClare OzawaΒ· per SEC Form D Β· $75M raise Β· filed Jun 2026

March Therapeutics, Inc.Sep 2022SEC filingmedium confidence

Cambridge, US

Board seatClare OzawaΒ· per SEC Form D Β· $30.3M raise Β· filed Sep 2022

Mistral TherapeuticsJun 2018SEC filingmedium confidence

BiotechSan Diego, US

Petpiboon Prasit(Director)Bradley Bolzon(Director)

BoardJeremy Caldwell(Executive Officer)

Board seatJerel DavisClare OzawaΒ· per SEC Form D Β· $59.3M raise Β· filed Jun 2018

Nexo Therapeutics, Inc.Mar 2026SEC filingmedium confidence

BiotechLittleton, US

Andrew Phillips(Executive Officer, Director)

BoardAli Behbahani(Director)

Board seatCarlo RizzutoΒ· per SEC Form D Β· $60M raise Β· filed Mar 2026

Pandion TherapeuticsJan 2018SEC filingmedium confidence

BiotechCambridge, US

Vikas Goyal(Director)Jo Viney(Executive Officer)Mitchell Mutz(Director)Anthony Coyle(Executive Officer, Director)

BoardAlan Crane(Director)

Board seatCarlo RizzutoΒ· per SEC Form D Β· $57.6M raise Β· filed Jan 2018

Pandion Therapeutics HoldcoMar 2020SEC filingmedium confidence

BiotechCambridge, US

Christopher Fuglesang(Director)Nancy Stagliano(Director)Donald Frail(Director)Mitchell Mutz(Director)Rahul Kakkar(Executive Officer, Director)Daniel Becker(Director)

Board seatCarlo RizzutoΒ· per SEC Form D Β· $80M raise Β· filed Apr 2020

Pep2Tango TherapeuticsNov 2024SEC filingmedium confidence

BiotechPotomac, US

Cristina Rondinone(Executive Officer, Director)

BoardMickey Kim(Director)Soumitra Ghosh(Director)

Board seatCarlo RizzutoΒ· per SEC Form D Β· $16.7M raise Β· filed Nov 2024

Presbyopia TherapiesMar 2023SEC filingmedium confidence

BiotechCoronado, US

MARK LESTER(MANAGER)JAMES McCOLLUM(MANAGER)GERALD HORN(MANAGER)

Board seatClare OzawaΒ· per SEC Form D Β· $83.5M raise Β· filed Mar 2023

Turnstone Biologicsturnstonebio.comJan 2019SEC filingmedium confidence

BiotechNew York, US

Jose Manuel Otero(Executive Officer)Robert Gould(Director)Jane Henderson(Executive Officer)Michael Burgess(Executive Officer)Stefan Larson(Director)Patrick Machado(Director)

Board seatBrad BolzonJerel DavisΒ· per SEC Form D Β· $42.1M raise Β· filed Jan 2019

Ventus Therapeuticsventustx.cominFeb 2022SEC filingmedium confidence

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechWaltham, US

Judith Lieberman(Co-Founder, MD, PhD)Daniel Koerwer(Executive Officer)Josh Resnick(Director)Steven James(Director)Michael Crackower(Executive Officer)Zachary McNealy(Executive Officer)

Board seatMarkus WarmuthJerel DavisΒ· per SEC Form D Β· $140M raise Β· filed Feb 2022

Akeroakerotx.comin𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Altergalterg.com

AlterG develops Anti-Gravity Treadmill systems that use patented NASA-inspired Differential Air Pressure (DAP) technology to reduce a user's body weight in precise increments, combined with gait analytics and video feedback.

HealthtechMedical DevicesSports Tech

Anokionanokion.com
Apreaaprea.com
BlueRock
Borealis
CRISPR Therapeutics
Enterprise Therapeuticsenterprisetherapeutics.comin𝕏

Enterprise Therapeutics develops novel drug therapies targeting the underlying mechanisms of mucus congestion in respiratory diseases including cystic fibrosis, asthma, and COPD.

BiotechHealthtechMedical Devices

Epix Therapeuticsin

Medtronic designs and develops medical technology for treating complex diseases.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Fable
Firefly
Inception 4 and 5
Kolm
Matterhorn Biosciences
Neli
Nested
Northern Biologics
Quanticel
Rayze Biorayzebio.comin

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Ken Song(Executive Officer, Director)Bong Koh(Director)Yi Larson(Director)

Repare Therapeutics
Santa Ana
Santa Ana Biosantaanabio.comin

Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.

BiotechMedical DevicesAlameda, US

Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)Thomas Woiwode(Director)

Second Sightsecondsight.app

Eye-tracking and human-state platform for clinical and consumer applications.

T-Knife
Tentarix
Ventus
Vividion Therapeuticsvividion.cominacquired by Bayer

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)

BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.